Dr @ZahiTouma discusses the attribution rules for the NPSLE syndromes Attribute to #SLE if - onset of NP is near the SLE dx - absence of concurrent nonSLE factors - ⬇️ frequency of NP events in the gen pop'n - diagnostic tools favor NPSLE @RheumNow #ACR24 https://t.co/e1xBK4Xzsw

Very informative slide describing the 2 NPSLE pathogenetic pathways & their differences in mediators, mechanisms and NP events. @RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/D3XFDqxMBq

Walsh et al. Direct mailing of PEST questionnaire to psoriasis patients. 13% PEST+, 4% seen by rheum (to date). 75% deemed appropriate for rheum to see - breakdown in picture. @RheumNow #ACR24 Abstr#2635 https://t.co/vlGJ977SV7 https://t.co/dbDUpwDZxy

Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf

A#2647 DADA2 cohort 101 pts in India Median delay dx 5 years - 5 pts of >20 yr - 39 pts w GI involvement- bad outcomes Skin most common - largely livedo, then ulcers/nodules CNS common w ischemia Many Rx before dx 12 deaths (11.8%) - 8 GI, 3 CVA, 1 suicide #ACR24 @RheumNow https://t.co/Q8kiVbJq8I

A call to action in diagnosing and treating NPSLE 👇 Wonderful talks by Dr @ZahiTouma Dr. Betty Diamond and Dr. Susanne Benseler @Rheumnow #ACR24 #lupus https://t.co/046ArRMP1a

Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs

SmPCs recommend interrupting immunosuppression (IS) in infection What happens if you continue the drug? Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection Could continuation be a safe option in some pts? #ACR24 @RheumNow https://t.co/14SN6a4Wm8

RIP to Glucocorticoids in GPA For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0

Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv

Study on #SLE and ESRD using machine learning: Developed model to identify patients with SLE and ESRD Used NIH 'All of Us' dataset XGBoost outperformed Random Forest SDOH data improved model precision #ACR24 @rheumnow #MachineLearning abst#1876 https://t.co/PQ7u4Pj5OH